Address
J.H. Oortweg 21
Leiden, 2333 CH
Netherlands (Kingdom of the)
Phone
31 71 203 6410
Website
Sector
Healthcare
Industry
Biotechnology
Employees
108
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Berndt Axel Edvard Modig | Co-Founder, Chief Executive Officer & Executive Director | 1.57M | 1959 |
| Maryann Cimino | Director of Corporate Relations | 0 | N/A |
| Wim Souverijns | Chief Commercial Officer | 0 | 1971 |
| Anna Nijdam | Head of Strategic Finance & Principal Accounting Officer | 0 | 1981 |
| Anne Lesage | Chief Early Development Officer | 0 | 1961 |
| Peng Lu | Chief Medical Officer | 0 | 1978 |
| Annick Deschoolmeester | Chief Human Resources Officer | 0 | 1973 |
| David W. Nassif | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | 0 | 1954 |
| Stefan Abele | Chief Technology Operations Officer | 0 | 1970 |
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and bringing to market treatments for uncommon diseases. Its primary pipeline asset, PHA121, is a small molecule bradykinin B2-receptor antagonist currently undergoing Phase II clinical trials for hereditary angioedema (HAE). Additionally, the company is advancing PHVS416, a swift-acting, on-demand soft capsule designed to alleviate acute HAE attacks, which is also in Phase 2 development. A third candidate, PHVS719, an extended-release prophylactic tablet aimed at preventing HAE episodes, is progressing through Phase 1 trials. Established in 2015 and headquartered in Leiden, the Netherlands, Pharvaris operates across the Netherlands, Switzerland, and the United States.